Cargando…
The Dilemma of Treating Delirium: the Conundrum of Drug Management
Delirium is a common medical complication in people living with cancer, particularly with more advanced disease. Delirium is associated with significant symptom burden which causes distress and impacts quality of life. As recommended by international guidelines, a high degree of suspicion is needed...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9174311/ https://www.ncbi.nlm.nih.gov/pubmed/35543960 http://dx.doi.org/10.1007/s11864-022-00987-9 |
_version_ | 1784722213649252352 |
---|---|
author | Agar, Meera R. Amgarth-Duff, Ingrid |
author_facet | Agar, Meera R. Amgarth-Duff, Ingrid |
author_sort | Agar, Meera R. |
collection | PubMed |
description | Delirium is a common medical complication in people living with cancer, particularly with more advanced disease. Delirium is associated with significant symptom burden which causes distress and impacts quality of life. As recommended by international guidelines, a high degree of suspicion is needed to ensure delirium is detected early. Attention to collateral history can provide clues to changes in cognition and attention. Non-pharmacological approaches that can be considered essential elements of care are effective in reducing the risk of delirium. Delirium screening using a validated measure is recommended as even expert clinicians can underdiagnose or miss delirium. The diagnostic assessment requires consideration of the cancer diagnosis and comorbidities, in the context of potential reversibility, goals of care, and patient preferences. The gold standard approach based on expert consensus is to institute management for delirium precipitants supported by non-pharmacological essential care, with the support of an interdisciplinary team. Medication management should be used sparingly and for a limited period of time wherever possible for severe perceptual disturbance or agitation which has not improved with non-pharmacological approaches. Clinicians should be familiar with the registered indication for medications and seek informed consent for off-label use. All interventions put in place to manage delirium need to consider net clinical benefit, including harms such as sedation and loss of capacity for meaningful interaction. Clear communication and explanation are needed regularly, with the person with delirium as far as possible and with surrogate decision makers. Delirium can herald a poor prognosis and this needs to be considered and be discussed as appropriate in shared decision-making. Recall after delirium has resolved is common, and opportunity to talk about this experience and the related distress should be offered during the period after recovery. |
format | Online Article Text |
id | pubmed-9174311 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-91743112022-06-09 The Dilemma of Treating Delirium: the Conundrum of Drug Management Agar, Meera R. Amgarth-Duff, Ingrid Curr Treat Options Oncol Palliative and Supportive Care (J Hardy, Section Editor) Delirium is a common medical complication in people living with cancer, particularly with more advanced disease. Delirium is associated with significant symptom burden which causes distress and impacts quality of life. As recommended by international guidelines, a high degree of suspicion is needed to ensure delirium is detected early. Attention to collateral history can provide clues to changes in cognition and attention. Non-pharmacological approaches that can be considered essential elements of care are effective in reducing the risk of delirium. Delirium screening using a validated measure is recommended as even expert clinicians can underdiagnose or miss delirium. The diagnostic assessment requires consideration of the cancer diagnosis and comorbidities, in the context of potential reversibility, goals of care, and patient preferences. The gold standard approach based on expert consensus is to institute management for delirium precipitants supported by non-pharmacological essential care, with the support of an interdisciplinary team. Medication management should be used sparingly and for a limited period of time wherever possible for severe perceptual disturbance or agitation which has not improved with non-pharmacological approaches. Clinicians should be familiar with the registered indication for medications and seek informed consent for off-label use. All interventions put in place to manage delirium need to consider net clinical benefit, including harms such as sedation and loss of capacity for meaningful interaction. Clear communication and explanation are needed regularly, with the person with delirium as far as possible and with surrogate decision makers. Delirium can herald a poor prognosis and this needs to be considered and be discussed as appropriate in shared decision-making. Recall after delirium has resolved is common, and opportunity to talk about this experience and the related distress should be offered during the period after recovery. Springer US 2022-05-11 2022 /pmc/articles/PMC9174311/ /pubmed/35543960 http://dx.doi.org/10.1007/s11864-022-00987-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Palliative and Supportive Care (J Hardy, Section Editor) Agar, Meera R. Amgarth-Duff, Ingrid The Dilemma of Treating Delirium: the Conundrum of Drug Management |
title | The Dilemma of Treating Delirium: the Conundrum of Drug Management |
title_full | The Dilemma of Treating Delirium: the Conundrum of Drug Management |
title_fullStr | The Dilemma of Treating Delirium: the Conundrum of Drug Management |
title_full_unstemmed | The Dilemma of Treating Delirium: the Conundrum of Drug Management |
title_short | The Dilemma of Treating Delirium: the Conundrum of Drug Management |
title_sort | dilemma of treating delirium: the conundrum of drug management |
topic | Palliative and Supportive Care (J Hardy, Section Editor) |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9174311/ https://www.ncbi.nlm.nih.gov/pubmed/35543960 http://dx.doi.org/10.1007/s11864-022-00987-9 |
work_keys_str_mv | AT agarmeerar thedilemmaoftreatingdeliriumtheconundrumofdrugmanagement AT amgarthduffingrid thedilemmaoftreatingdeliriumtheconundrumofdrugmanagement AT agarmeerar dilemmaoftreatingdeliriumtheconundrumofdrugmanagement AT amgarthduffingrid dilemmaoftreatingdeliriumtheconundrumofdrugmanagement |